Cochrane · systematic review · CD009211
The role of additional radiotherapy for primary central nervous system lymphoma
Zacher, J, Kasenda, B, Engert, A, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
4
No studies
2
Included studies
NR
No studies 2 · 33.3%Ungraded 0 · 0%Very low 2 · 33.3%Low 1 · 16.7%Moderate 1 · 16.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Additional radiotherapy for PCNSL
Population: Participants with PCNSL
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (instead of OS) | HR 1.01 [0.79, 1.3] | 1 study · 411 participants | Moderate Downgraded: risk of bias, imprecision |
Relapses/death (instead of PFS) | HR 0.79 [0.63, 0.99] | 1 study · 411 participants | Low Downgraded: risk of bias, imprecision |
Treatment‐related mortality | no estimate extracted | NR | No studies |
Adverse events: treatment‐related neurotoxicity | RR 1.85 [0.98, 3.48] | 1 study · 79 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events: delayed neurotoxicity | no estimate extracted | 1 study · 84 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life | no estimate extracted | NR | No studies |